Brazil restricts polilaminina therapy after 9 deaths; company denies link

Brazilian health authorities imposed restrictions on the use of polilaminina therapy following nine reported deaths, though the pharmaceutical company disputes any causal relationship. The measure signals a regulatory response to a potential safety signal, but the evidence base and scope of restrictions remain unclear. This matters as it could affect patient access and company liability, though market impact is likely limited.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works